ORAGENICS

oragenics-logo

Oragenics are a biopharmaceutical company focused primarily on oral probiotics products and novel antibiotics for humans and companion pets. Within oral health we are commercializing our patented probiotic blend, ProBiora3® specifically formulated for oral health both under our branded Evora line and in private label configurations. Currently we have sales or contracts to sell these products in over 15 countries around the world. Our recent partnership with Intrexon in the field of Lantibiotics... , a largely overlooked class of extremely potent gram-positive antibiotics, will help us to develop our pharmaceutical product candidate, MU1140-S™ and additional antibiotics from the Lantibiotic class for therapeutic use. The focus on the probiotic area will be to grow sales through a variety of channels including internet sales and the professional channel (dentists and hygienists) as well as through private label and bulk sales of our patented ProBiora3 blend. We intend to look for opportunities to expand our health claims for these products through a range of clinical studies. We are also looking at novel and convenient new delivery systems for our probiotics, which we plan to commercialize in the near future. In 2011 we received the Frost and Sullivan Award for excellence in probiotics. This was a competitive award that placed us as a leader in the probiotic space.

#People #Financial #Website #More

ORAGENICS

Social Links:

Industry:
Biotechnology Health Care Pharmaceutical Therapeutics

Founded:
1996-01-01

Address:
Tampa, Florida, United States

Country:
United States

Website Url:
http://www.oragenics.com

Total Employee:
11+

Status:
Active

Contact:
(813)286-7900

Total Funding:
98.84 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Apache Microsoft Exchange Online



Current Advisors List

not_available_image

Christine Koski Board Member @ Oragenics
Board_member
2009-01-01

Current Employees Featured

alan-joslyn_image

Alan Joslyn
Alan Joslyn President and Chief Executive Officer @ Oragenics
President and Chief Executive Officer

not_available_image

Michael Sullivan
Michael Sullivan CFO @ Oragenics
CFO
2012-02-01

Founder


not_available_image

Jeffrey Hillman

not_available_image

Robert Zahradnik

Stock Details


Company's stock symbol is NYSEMKT:OGEN

Acquisitions List

Date Company Article Price
2006-11-20 iviGene iviGene acquired by Oragenics N/A

Official Site Inspections

http://www.oragenics.com Semrush global rank: 4.85 M Semrush visits lastest month: 1.83 K

  • Host name: ec2-174-129-30-187.compute-1.amazonaws.com
  • IP address: 174.129.30.187
  • Location: Ashburn United States
  • Latitude: 39.0481
  • Longitude: -77.4728
  • Metro Code: 511
  • Timezone: America/New_York
  • Postal: 20149

Loading ...

More informations about "Oragenics"

About :: Oragenics, Inc. (OGEN)

See details»

Profile :: Oragenics, Inc. (OGEN)

Address: 4902 Eisenhower Blvd. Suite 125 Tampa, FL 33634 . Telephone: 813-286-7900. Fax: 813-286-7900. Email: [email protected]See details»

Oragenics - Crunchbase Company Profile & Funding

Oragenics is a development-stage company that primarily engages in fighting infectious diseases, including coronaviruses and multidrug-resistant organisms. Its lead product is an intranasal vaccine candidate to provide long-lasting …See details»

Investor Relations :: Oragenics, Inc. (OGEN)

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit. Oct 18, 2024. Read Press Release. Upcoming Event. 2023 Annual Meeting of Shareholders . …See details»

Oragenics - Overview, News & Similar companies | ZoomInfo.com

Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms Its lead product is NT-CoV2-1, an …See details»

Vaccine Program :: Oragenics, Inc. (OGEN)

Oragenics is positioning its NT-CoV-2 candidate to compete in this later phase of the COVID-19 vaccine market. Novel Approach & Opportunity. ... Inspirevax is a Contract Manufacturing …See details»

Oragenics, Inc. Files 10K and Provides Company Update

Apr 1, 2024 Contracted with a leading Contract Research Organization to oversee our Phase II clinical trial. ... Oragenics, Inc. Janet Huffman, Chief Financial Officer 813-286-7900 …See details»

Oragenics, Inc. (OGEN) Company Profile & Facts - Yahoo Finance

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the …See details»

Oragenics, Inc. Files 10K and Provides Company Update - Yahoo …

SARASOTA, Fla., April 01, 2024--Oragenics, Inc. (the "Company") (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of …See details»

Oragenics Inc. and Aragen Bioscience Enter Agreement to …

TAMPA, Fla. & MORGAN HILL, Calif.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN), (the “Company” or “Oragenics”), today announced, that through its wholly-owned …See details»

Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy …

TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including …See details»

Oragenics Enters into Licensing Agreement with the National …

Jul 27, 2021 Oragenics, Inc. Michael Sullivan, Chief Financial Officer 813-286-7900 [email protected] or LHA Investor Relations Kim Golodetz 212-838-3777 …See details»

Collaborations :: Oragenics, Inc. (OGEN)

The NRC is Canada’s largest federal research and development organization, partnering with Canadian industries to take research from the lab to the marketplace. In July 2021, Oragenics’ …See details»

Oragenics, Inc. Files 10K and Provides Company Update

Apr 1, 2024 Oragenics, Inc. Janet Huffman, Chief Financial Officer 813-286-7900 [email protected] LHA Investor Relations Tirth T. Patel 212-201-6614 [email protected]See details»

Oragenics, Inc. Announces Conversion of Preferred Shares

23 hours ago Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including …See details»

Oragenics Enters into Licensing Agreement with the National …

Jul 27, 2021 TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) today announced it has entered into a licensing agreement with the National Research Council of …See details»

Oragenics, Inc. Announces Conversion of Preferred Shares and ...

Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug …See details»

Oragenics, Inc. Completes Conversion of Preferred Shares to

23 hours ago Oragenics converted Series A and B Preferred Shares into common stock, simplifying its capital structure and eliminating $2.35 million in liquidation preference. …See details»

Oragenics, Inc. Announces Conversion of Preferred Shares and ...

23 hours ago SARASOTA, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE: OGEN), a biotechnology company advancing innovative treatments for brain-related health …See details»

Oragenics Extends Collaboration with the National Research …

Dec 20, 2021 TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced it has extended a licensing and collaboration …See details»